Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Evommune, Inc.

Criteria

Inclusion Criteria:

1. Males or non-pregnant, non-lactating females, age 18 years or older

2. Chronic atopic dermatitis for at least 1 year

3. IGA score of 2 or 3

4. BSA of AD involvement of 4-12%

5. EASI of 5-20

Exclusion Criteria:

1. Significant AD flare with 4 weeks

2. Use of biologic therapy within 12 weeks

3. Regular use of tanning booth within 4 weeks

4. Skin condition that could interfere with study assessments